A group of cannabis clinicians in Colorado is recruiting a total of sixteen retired elite athletes to take part in a study investigating how CBD products improve their quality of life with respect to combating chronic pain, helping them sleep better, and any other effects.
Cannabis Clinicians Colorado says that those who played sports at college level or professionally for at least one year can apply to be screened and selected if they meet the participation criteria.
CCC says that they are focusing on former elite athletes because getting to that competitive level requires a lot of work and that often comes with sports-related injuries that could last long after one’s playing career ends.
Martha Montemayor, the director of CCC, says that many athletes have incorporated CBD into their workout and recovery routines, and a lot of these people provide personal testimonies of how much they have benefited from those products. However, there isn’t enough scientific evidence to back up or refute that anecdotal evidence, so this study is intended to provide some answers about the authenticity of the benefits attributed to CBD among athletes.
The CCC staff will analyze the feedback provided by the former elite athletes who participate in the study. The intention is to find out which CBD products, such as topicals and tinctures, work best to bring relief from a variety of mental and physical conditions.
Montemayor also says that the researchers will be interested in finding out whether there is a particular CBD dosage which delivers the best results among the study subjects.
The study will have an “active period” lasting eight weeks. During this time, study participants will be given increasing doses of CBD products which will peak at 100mg a day. The starting dose will be 25mg.
After those initial eight weeks, the participants will be taken off the CBD for a month and they will be asked to keep a journal detailing how long the effects the applicants felt last once the intake of CBD is halted.
In addition to the self-reported effects provided by the participants, the researchers will subject the subjects to electroencephalogram tests so that the brain patterns of the participants are recorded while they are taking the CBD products and during the time when they aren’t using CBD.
The researchers want to use the findings of this less-than-rigorous trial to trigger the undertaking of more clinical research using their findings as a basis. CCC will also conduct its own additional analysis of the products that stand out during this investigative study.
Analysts believe industry players like TransCanna Holdings Inc. (CSE: TCAN) (FRA: TH8) and VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) are glad that independent entities are coming out to test and confirm what the CBD industry has known for long about the effects of CBD upon athletes.
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
